|
|
2B182C |
|
Vaxjo ID |
115 |
|
Vaccine Adjuvant Name |
2B182C |
|
Adjuvant VO ID |
VO_0005271
|
|
Description |
small molecule with TLR4 receptor; induces mucosal immunity, promotes antibody epitope spreading, and is anti-inflmmatory |
|
Stage of Development |
Research |
|
Location Licensed |
US (UCSD) |
|
Host Species for Testing |
Mouse |
|
Components |
liposome, occassionaly used with TLR7 ligand; small molecule TLR4 agonist = 1Z105 and phospholipid conjugated small molecule TLR7 ligand = 1V270 |
|
Storage |
"Formulated material at 4C for 6 months Solid form is stable at 4C for > 2 years" |
|
Preparation |
co-encapsulated in liposomes, and these liposomal formulations were prepared by the lipid film rehydration method using DOPC:cholesterol in a molar ratio of 2:1 (1V270: 2B182C) |
|
Function |
Type: TLR agonist vaccine adjuvant. Target Receptor: Toll-like receptor 4 (TLR4). Induces Th1/Th2 mixed immune profile innate immune activation, specifically against influenza |
| References |
(Carson, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=7]
Goff et al., 2015: Goff PH, Hayashi T, MartÃnez-Gil L, Corr M, Crain B, Yao S, Cottam HB, Chan M, Ramos I, Eggink D, Heshmati M, Krammer F, Messer K, Pu M, Fernandez-Sesma A, Palese P, Carson DA. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. Journal of virology. 2015; 89(6); 3221-3235. [PubMed: 25568203].
|
|
